Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ando.2020.05.001 http://scihub22266oqcxt.onion/10.1016/j.ando.2020.05.001 32413342!7217100!32413342     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Ann+Endocrinol+(Paris) 2020 ; 81 (2-3): 101-109 Nephropedia Template TP {{tp|p=32413342|t=2020. COVID-19 in diabetic patients: Related risks and specifics of management |pdf=|usr=}}{{32413342}} gab.com Text COVID-19 in diabetic patients: Related risks and specifics of management JO: Ann Endocrinol (Paris) http://www.kidney.de/pget.php?&tw=1&pmid=32413342 #FOAvip Diabetes is among the most frequently reported comorbidities in patients infected with COVID-19. According to current data, diabetic patients do not appear to be at increased risk of contracting SARS-CoV-2 compared to the general population. On the other hand, diabetes is a risk factor for developing severe and critical forms of COVID-19, the latter requiring admission to an intensive care unit and/or use of invasive mechanical ventilation, with high mortality rates. The characteristics of diabetic patients at risk for developing severe and critical forms of COVID-19, as well as the prognostic impact of diabetes on the course of COVID-19, are under current investigation. Obesity, the main risk factor for incident type 2 diabetes, is more common in patients with critical forms of COVID-19 requiring invasive mechanical ventilation. On the other hand, COVID-19 is usually associated with poor glycemic control and a higher risk of ketoacidosis in diabetic patients. There are currently no recommendations in favour of discontinuing antihypertensive medications that interact with the renin-angiotensin-aldosterone system. Metformin and SGLT2 inhibitors should be discontinued in patients with severe forms of COVID-19 owing to the risks of lactic acidosis and ketoacidosis. Finally, we advise for systematic screening for (pre)diabetes in patients with proven COVID-19 infection. Twit Text FOAVip COVID-19 in diabetic patients: Related risks and specifics of management ????Ann Endocrinol (Paris) http://www.kidney.de/pget.php?&tw=1&pmid=32413342 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32413342 #FOAvip English Wikipedia <ref>{{Cite pmid|32413342}}</ref> COVID-19 in diabetic patients: Related risks and specifics of management #MMPMID32413342 Orioli L; Hermans MP; Thissen JP; Maiter D; Vandeleene B; Yombi JC Ann Endocrinol (Paris) 2020[Jun]; 81 (2-3): 101-109 PMID32413342show ga Diabetes is among the most frequently reported comorbidities in patients infected with COVID-19. According to current data, diabetic patients do not appear to be at increased risk of contracting SARS-CoV-2 compared to the general population. On the other hand, diabetes is a risk factor for developing severe and critical forms of COVID-19, the latter requiring admission to an intensive care unit and/or use of invasive mechanical ventilation, with high mortality rates. The characteristics of diabetic patients at risk for developing severe and critical forms of COVID-19, as well as the prognostic impact of diabetes on the course of COVID-19, are under current investigation. Obesity, the main risk factor for incident type 2 diabetes, is more common in patients with critical forms of COVID-19 requiring invasive mechanical ventilation. On the other hand, COVID-19 is usually associated with poor glycemic control and a higher risk of ketoacidosis in diabetic patients. There are currently no recommendations in favour of discontinuing antihypertensive medications that interact with the renin-angiotensin-aldosterone system. Metformin and SGLT2 inhibitors should be discontinued in patients with severe forms of COVID-19 owing to the risks of lactic acidosis and ketoacidosis. Finally, we advise for systematic screening for (pre)diabetes in patients with proven COVID-19 infection. |Acidosis, Lactic/chemically induced/epidemiology/virology[MESH] |Betacoronavirus/physiology[MESH] |COVID-19[MESH] |Comorbidity[MESH] |Coronavirus Infections/*complications/diagnosis/epidemiology/*therapy[MESH] |Critical Illness/epidemiology/therapy[MESH] |Diabetes Mellitus, Type 2/*complications/diagnosis/epidemiology/*therapy[MESH] |Diabetic Ketoacidosis/chemically induced/epidemiology/virology[MESH] |Humans[MESH] |Mass Screening/methods/standards[MESH] |Metformin/therapeutic use[MESH] |Obesity/complications/epidemiology/therapy[MESH] |Pandemics[MESH] |Pneumonia, Viral/*complications/diagnosis/epidemiology/*therapy[MESH] |Prediabetic State/complications/diagnosis/epidemiology/therapy[MESH] |Renin-Angiotensin System/physiology[MESH] |Risk Factors[MESH] |Risk Management[MESH] |SARS-CoV-2[MESH] |Severity of Illness Index[MESH] |Sodium-Glucose Transporter 2 Inhibitors/therapeutic use[MESH]COVID-19 in diabetic patients: Related risks and specifics of manageme(epmc).pdf DeepDyve Pubget Overpricing